What we do Aether Industries Ltd is a fast-growing specialty chemical manufacturer in India, producing advanced intermediates for pharmaceuticals, agrochemicals, and high-performance materials. |
Founded in 2,013 |
Market share Largest Indian producer and global volume leader for several specialty chemicals like 4MEP, T2E, and NODG. |
Problem solved Develops complex specialty chemicals addressing needs of pharmaceutical, agrochemical, and material science industries worldwide. |
Top clients or who we serve Serves global pharmaceutical, agrochemical, specialty chemical sectors via B2B and contract manufacturing models. |
Key management Ashwin Jayantilal Desai (Managing Director) leads with extensive industry experience; Dr. James William Ringer appointed CTO in 2024. |
Our journey and innovations Started in 2013, key milestones include launch of signature chemicals and expansion with four manufacturing facilities and in-house R&D. |
Where we operate Operations in India with significant exports globally; facilities in Gujarat support large-scale manufacturing and R&D. |
Top products or what we offer Flagship products include 4MEP, OTBN, MMBC under business models of large-scale manufacturing, CRAMS, and exclusive manufacturing. |
Top brands Leading specialty chemicals: 4MEP (largest worldwide), T2E, MMBC, OTBN; recognized for quality and volume leadership. |
Raw materials needed Specialty chemicals synthesis requires solvents, intermediates, and technical-grade raw materials sourced globally. |
Raw materials supplier Procures materials from global chemical suppliers; specifics not publicly detailed. |
Recurring vs cyclical contribution Revenue mix includes recurring contract manufacturing and project-based manufacturing services. |
Our industry position Among India’s specialty chemical leaders with global ranking in volumes for key products and a growing CRAMS portfolio. |
Financial highlights FY24 revenue ₹6,374 million, EBITDA ₹1,714 million, PAT ₹825 million; strong growth post recovery from 2023 accident. |
Geographical revenue split Approximately 60% domestic and 40% export revenues, with global client base across multiple sectors. |
Order book Robust order book driven by expanding CRAMS and exclusive manufacturing contracts with 36+ customer audits FY26. |
Whats driving growth Growth fueled by expanding contract manufacturing, new facility commissioning, and increasing pharmaceutical and agrochemical demand. |
Our future plans Scaling operations with Site 5 expansion, new blocks operational from March 2026; focused R&D and capacity enhancement. |
Our green promise Committed to sustainability with solar power plants, solvent recovery, and compliance with ISO and Indian GMP standards. |
Our people and values Over 140 R&D scientists, fostering innovation and diversity in a young, motivated workforce averaging 30 years of age. |
Key challenges ahead Managing operational risks post-accident, maintaining safety and environmental compliance, and sustaining growth momentum. |
Interesting facts Sole Indian manufacturer of multiple signature chemicals; commissioned 16 MW solar power plant; strong R&D collaborations. |
Risks and strategy Mitigates risks through rigorous safety protocols, diversified business models, and continuous technology innovation. |
